Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

Exclusion Criteria

• •1. Pancoast tumor, squamous cell carcinoma, large-cell carcinoma and sarcomatoid carcinoma;
• •2. Patients with active autoimmune disease or history of autoimmune disease;
• •3. Patients who have a condition requiring systemic treatment with either prednisone or other immunosuppressive medications;
• •4. Patients with a history of symptomatic interstitial lung disease;
• •5. History of allergy to study drug components;
• •6. Women must not be pregnant or breast-feeding;
• •7. Men with female partners that are not willing to use contraception;
• •8. Patients who have received prior chemotherapy, anti-angiogenesis therapy and immunotherapy for this malignancy or for any other past malignancy;
• •9. Patients who have received prior treatment for non-small cell lung cancer;
• •10. Any mental or psychological condition which would not permit the patient to complete the study or understand the patient information;
• •11. Patients who have major hemoptysis within the past 4 weeks, tumor has invasion or is close to great vessels;
• •12. Patients with high risk of major bleeding;
• •13. Patients who have arterial thrombotic events, esophageal varices, peptic ulcers, wounds or bone fractures;
• •14. Patients who have prior malignancies;
• •15. HIV, HBV, HCV infection or active pulmonary tuberculosis;
• •16. Underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events.